Literature DB >> 2140946

Relationship between positive inotropic responses and plasma concentrations of xamoterol in middle-aged and elderly patients.

H F Marlow1, F L Hine, H M Snow, H Pouleur, M F Rousseau.   

Abstract

1. We examined the relationship between the contractile state of the left ventricle and the plasma concentration of xamoterol in patients with ischaemic heart failure. 2. Identical studies were conducted in 14 middle-aged (all male; mean age 51.3 years, range 42-61) and 10 elderly patients (six male, four female; mean age 67.7 years, range 64-72). 3. Patients received seven cumulative doses (0.0005-0.2 mg kg-1) of xamoterol. After each dose the rate of change of pressure in the left ventricle at a developed pressure of 40 mm Hg and normalised for this pressure, (dP/dt)/DP40, and plasma concentrations of xamoterol were measured. 4. There were dose-related increases in (dP/dt)/DP40. Curves relating changes in (dP/dt)/DP40, expressed as a percent of the maximum observed response, to changes in xamoterol plasma concentrations were constructed for the middle-aged and elderly patients. From these curves the mean effective concentration (EC) value to produce a particular response could be calculated. In the sample sizes studied, the difference between the EC values over a range of responses for the middle-aged and elderly patients did not reach statistical significance, indicating that cardiac responsiveness to xamoterol was similar in the two groups of patients. 5. Plasma concentrations of xamoterol over the range of 39 to 150 ng ml-1 produced positive inotropic responses which varied between 70% and 90% of the maximum observed effect of xamoterol.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140946      PMCID: PMC1380149          DOI: 10.1111/j.1365-2125.1990.tb03673.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility.

Authors:  R E Weishaar; D C Kobylarz-Singer; R P Steffen; H R Kaplan
Journal:  Circ Res       Date:  1987-10       Impact factor: 17.367

2.  Effect of ICI 118,587 on left ventricular function during graded treadmill exercise in conscious dogs.

Authors:  A Ohyagi; S Sasayama; Y Nakamura; J D Lee; Y Kihara; C Kawai
Journal:  Am J Cardiol       Date:  1984-11-01       Impact factor: 2.778

3.  Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers.

Authors:  W Bastain; M J Boyce; L E Stafford; P B Morton; D A Clarke; H F Marlow
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction.

Authors:  H Sato; M Inoue; T Matsuyama; H Ozaki; T Shimazu; H Takeda; Y Ishida; T Kamada
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

5.  Effect of xamoterol (ICI 118587), a new beta1 adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction.

Authors:  A O Molajo; D H Bennett
Journal:  Br Heart J       Date:  1985-07

6.  Hemodynamic effects of vasodilators and long-term response in heart failure.

Authors:  J A Franciosa; W B Dunkman; C L Leddy
Journal:  J Am Coll Cardiol       Date:  1984-06       Impact factor: 24.094

7.  The acute effects of intravenous xamoterol ('Corwin', I.C.I. 118, 587) on resting and exercise haemodynamics in patients with mild to moderate heart failure.

Authors:  S J Virk; N H Anfilogoff; N Lawson; A M Sadler; S J Smith; A Nuttall; R G Murray; W A Littler; M K Davies
Journal:  Eur Heart J       Date:  1989-03       Impact factor: 29.983

8.  The metabolism of ICI 118,587, a partial agonist of beta 1-adrenoceptors, in mice, rats, rabbits, dogs, and humans.

Authors:  T R Marten; G R Bourne; G S Miles; B Shuker; H D Rankine; V N Dutka
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

9.  Haemodynamic effects of ICI 118,587 in cardiomyopathy.

Authors:  S Simonsen
Journal:  Br Heart J       Date:  1984-06

10.  How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men.

Authors:  M Packer
Journal:  J Am Coll Cardiol       Date:  1987-02       Impact factor: 24.094

View more
  1 in total

1.  The lipolytic effect of beta 1- and beta 2-adrenoceptor activation in healthy human volunteers.

Authors:  C A Haffner; M J Kendall; S Maxwell; B Hughes
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.